CCT greater in the hypertensive

Article

Greater central corneal thickness (CCT) measurements are observed in those with ocular hypertension than in those without, according to a report published online ahead of publication in Ophthalmology.

Greater central corneal thickness (CCT) measurements are observed in those with ocular hypertension than in those without, according to a report published online ahead of publication in Ophthalmology.

Researchers involved in the European Glaucoma Prevention Study Group (EGPS), conducted a randomized, double-masked, controlled, observational clinical trial of 854 of the patients enrolled in EGPS. A total of 429 patients were treated with dorzolamide and 425 received a placebo. CCT thickness was measured by ultrasound pachymetry and measurements were taken in the morning before intraocular pressure (IOP). Five measurements were taken from each eye of each patient within five minutes of application of anaesthetic eye drops.

Results showed that mean CCT was 572.6±37.4 µm (range 458.5 – 695.6 µm). CCT was higher in younger patients, male patients and diabetic patients. Mean CCT measurements for the dorzolamide patients was recorded at 574.2±38.48 µm (range 458.5 – 695.6 µm) and for the placebo patients, 571.0±36.21 µm (rage 469.7 – 690.1 µm). CCT did not correlate with refraction, baseline IOP or systemic hypertension.

The researchers found that CCT measurements for those with ocular hypertension are higher than for those without the condition.

Recent Videos
Dr Rick Lewis discusses the FLigHT procedure and ViaLase laser at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) meeting
Christiana Dinah speaks about her ASRS presentation, Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Related Content
© 2024 MJH Life Sciences

All rights reserved.